Bioinformatical analysis of the key differentially expressed genes for screening potential biomarkers in Wilms tumor.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 09 2023
16 09 2023
Historique:
received:
22
05
2023
accepted:
14
09
2023
medline:
18
9
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
epublish
Résumé
Wilms tumor (WT) is the most common pediatric renal malignant tumor in the world. Overall, the prognosis of Wilms tumor is very good. However, the prognosis of patients with anaplastic tumor histology or disease relapse is still poor, and their recurrence rate, metastasis rate and mortality are significantly increased compared with others. Currently, the combination of histopathological examination and molecular biology is essential to predict prognosis and guide the treatment. However, the molecular mechanism has not been well studied. Genetic profiling may be helpful in some way. Hence, we sought to identify novel promising biomarkers of WT by integrating bioinformatics analysis and to identify genes associated with the pathogenesis of WT. In the presented study, the NCBI Gene Expression Omnibus was used to download two datasets of gene expression profiles related to WT patients for the purpose of detecting overlapped differentially expressed genes (DEGs). The DEGs were then uploaded to DAVID database for enrichment analysis. In addition, the functional interactions between proteins were evaluated by simulating the protein-protein interaction (PPI) network of DEGs. The impact of selected hub genes on survival in WT patients was analyzed by using the online tool R2: Genomics Analysis and Visualization Platform. The correlation between gene expression and the degree of immune infiltration was assessed by the Estimation of Stromal and Immune cells in Malignant Tumor tissues using the Expression (ESTIMATE) algorithm and the single sample GSEA. Top 12 genes were identified for further study after constructing a PPI network and screening hub gene modules. Kinesin family member 2C (KIF2C) was identified as the most significant gene predicting the overall survival of WT patients. The expression of KIF2C in WT was further verified by quantitative real-time polymerase chain reaction and immunohistochemistry. Furthermore, we found that KIF2C was significantly correlated with immune cell infiltration in WT. Our present study demonstrated that altered expression of KIF2C may be involved in WT and serve as a potential prognostic biomarker for WT patients.
Identifiants
pubmed: 37717078
doi: 10.1038/s41598-023-42730-w
pii: 10.1038/s41598-023-42730-w
pmc: PMC10505208
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15404Informations de copyright
© 2023. Springer Nature Limited.
Références
Tian, F., Yourek, G., Shi, X. & Yang, Y. The development of Wilms tumor: From WT1 and microRNA to animal models. Biochim. Biophys. Acta 2014, 180–187 (1846).
Treger, T. D., Chowdhury, T., Pritchard-Jones, K. & Behjati, S. The genetic changes of Wilms tumour. Nat. Rev. Nephrol. 15, 240–251 (2019).
pubmed: 30705419
Spreafico, F. et al. Wilms tumour. Nat. Rev. Dis. Primers 7, 75 (2021).
pubmed: 34650095
Zhou, R. et al. CircCDYL acts as a tumor suppressor in Wilms’ tumor by targeting miR-145-5p. Front. Cell Dev. Biol. 9, 668947 (2021).
pubmed: 34485273
pmcid: 8415843
Parsons, L. N. Wilms tumor: Challenges and newcomers in prognosis. Surg. Pathol. Clin. 13, 683–693 (2020).
pubmed: 33183727
Ooms, A. H. et al. Significance of TP53 mutation in Wilms tumors with diffuse anaplasia: A report from the children’s oncology group. Clin. Cancer Res. 22, 5582–5591 (2016).
pubmed: 27702824
pmcid: 5290091
Maschietto, M. et al. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS ONE 9, e109924 (2014).
pubmed: 25313908
pmcid: 4196953
Phelps, H. M., Kaviany, S., Borinstein, S. C. & Lovvorn, H. N. 3rd. Biological drivers of Wilms tumor prognosis and treatment. Children (Basel) 5, 145 (2018).
pubmed: 30373137
Theiss, A. L. & Sitaraman, S. V. The role and therapeutic potential of prohibitin in disease. Biochim. Biophys. Acta 2011, 1137–1143 (1813).
Walz, A. L. et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27, 286–297 (2015).
pubmed: 25670082
pmcid: 4800737
Zhang, L. et al. Identification of key genes and microRNAs involved in kidney Wilms tumor by integrated bioinformatics analysis. Exp. Ther. Med. 18, 2554–2564 (2019).
pubmed: 31555364
pmcid: 6755433
Scott, R. H., Stiller, C. A., Walker, L. & Rahman, N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J. Med. Genet. 43, 705–715 (2006).
pubmed: 16690728
pmcid: 2564568
Pelosi, A. et al. Pediatric tumors-mediated inhibitory effect on NK cells: The case of neuroblastoma and Wilms’ tumors. Cancers (Basel) 13, 2374 (2021).
pubmed: 34069127
Ren, X. & Zhang, Z. Understanding tumor-infiltrating lymphocytes by single cell RNA sequencing. Adv. Immunol. 144, 217–245 (2019).
pubmed: 31699218
Kulasingam, V. & Diamandis, E. P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5, 588–599 (2008).
pubmed: 18695711
Jiang, P. & Liu, X. S. Big data mining yields novel insights on cancer. Nat. Genet. 47, 103–104 (2015).
pubmed: 25627899
Mahamdallie, S. et al. Identification of new Wilms tumour predisposition genes: An exome sequencing study. Lancet Child Adolesc. Health 3, 322–331 (2019).
pubmed: 30885698
pmcid: 6472290
Cone, E. B. et al. Biomarkers for wilms tumor: A systematic review. J. Urol. 196, 1530–1535 (2016).
pubmed: 27259655
pmcid: 5069120
Kinoshita, K., Noetzel, T. L., Arnal, I., Drechsel, D. N. & Hyman, A. A. Global and local control of microtubule destabilization promoted by a catastrophe kinesin MCAK/XKCM1. J. Muscle Res. Cell Motil. 27, 107–114 (2006).
pubmed: 16450057
Tanenbaum, M. E., Medema, R. H. & Akhmanova, A. Regulation of localization and activity of the microtubule depolymerase MCAK. BioArchitecture 1, 80–87 (2011).
pubmed: 21866268
pmcid: 3158623
Banks, J. D. & Heald, R. Chromosome movement: Dynein-out at the kinetochore. Curr. Biol. 11, R128–R131 (2001).
pubmed: 11250166
Shimo, A. et al. Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 99, 62–70 (2008).
pubmed: 17944972
Ishikawa, K. et al. Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. Br. J. Cancer 98, 1824–1829 (2008).
pubmed: 18506187
pmcid: 2410130
Holmfeldt, P., Zhang, X., Stenmark, S., Walczak, C. E. & Gullberg, M. CaMKIIgamma-mediated inactivation of the Kin I kinesin MCAK is essential for bipolar spindle formation. EMBO J. 24, 1256–1266 (2005).
pubmed: 15775983
pmcid: 556404
Ritter, A., Kreis, N. N., Louwen, F., Wordeman, L. & Yuan, J. Molecular insight into the regulation and function of MCAK. Crit. Rev. Biochem. Mol. Biol. 51, 228–245 (2015).
pubmed: 27146484
Gan, H. et al. KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR-325-3p. Cell Biochem. Funct. 37, 424–431 (2019).
pubmed: 31328811
An, L. et al. KIF2C is a novel prognostic biomarker and correlated with immune infiltration in endometrial cancer. Stem Cells Int. 2021, 1434856 (2021).
pubmed: 34650608
pmcid: 8510809
Bie, L., Zhao, G., Wang, Y. P. & Zhang, B. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clin. Neurol. Neurosurg. 114, 356–360 (2012).
pubmed: 22130050
Ludwig, N. et al. Combining miRNA and mRNA expression profiles in Wilms tumor subtypes. Int. J. Mol. Sci. 17, 475 (2016).
pubmed: 27043538
pmcid: 4848931
Su, C. et al. Identification of key genes associated with cancer stem cell characteristics in Wilms’ tumor based on bioinformatics analysis. Ann. Transl. Med. 10, 1204 (2022).
pubmed: 36544656
pmcid: 9761159
Kort, E. J. et al. The E2F3-Oncomir-1 axis is activated in Wilms’ tumor. Cancer Res. 68, 4034–4038 (2008).
pubmed: 18519660
pmcid: 2442735
Wu, S., Wu, F. & Jiang, Z. Identification of hub genes, key miRNAs and potential molecular mechanisms of colorectal cancer. Oncol. Rep. 38, 2043–2050 (2017).
pubmed: 28902367
pmcid: 5652954
Sherman, B. T. et al. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (update). Nucleic Acids Res. 50, W216–W221 (2022).
pubmed: 35325185
pmcid: 9252805
Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015).
pubmed: 25352553
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658
pmcid: 403769
Bader, G. D. & Hogue, C. W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 4, 2 (2003).
Chin, C. H. et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8(Suppl 4), S11 (2014).
pubmed: 25521941
pmcid: 4290687
Gadd, S. et al. A Children’s Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat. Genet. 49, 1487–1494 (2017).
pubmed: 28825729
pmcid: 5712232
Jurić, I. et al. Expression and prognostic value of the Ki-67 in Wilms’ tumor: Experience with 48 cases. Pediatr. Surg. Int. 26, 487–493 (2010).
pubmed: 20306058
Beniers, A. J. et al. p53 expression in Wilms’ tumor: A possible role as prognostic factor. Int. J. Oncol. 18, 133–139 (2001).
pubmed: 11115550
Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997–4013 (2013).
pubmed: 24101045
Marchiò, C. et al. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin. Cancer Biol. 72, 123–135 (2021).
pubmed: 32112814
Wang, W. et al. Insight into microtubule disassembly by kinesin-13s from the structure of Kif2C bound to tubulin. Nat. Commun. 8, 70 (2017).
pubmed: 28694425
pmcid: 5503940
Wordeman, L. Microtubule-depolymerizing kinesins. Curr. Opin. Cell Biol. 17, 82–88 (2005).
pubmed: 15661523
Wordeman, L. & Mitchison, T. J. Identification and partial characterization of mitotic centromere-associated kinesin, a kinesin-related protein that associates with centromeres during mitosis. J. Cell Biol. 128, 95–104 (1995).
pubmed: 7822426
Moore, A. & Wordeman, L. The mechanism, function and regulation of depolymerizing kinesins during mitosis. Trends Cell Biol. 14, 537–546 (2004).
pubmed: 15450976
Ritter, A. et al. Functional analysis of phosphorylation of the mitotic centromere-associated kinesin by Aurora B kinase in human tumor cells. Cell Cycle 14, 3755–3767 (2015).
pubmed: 26148251
pmcid: 4825789
Eichenlaub-Ritter, U. Microtubule dynamics and tumor invasion involving MCAK. Cell Cycle 14, 3353 (2015).
pubmed: 26375511
pmcid: 4825562
Bai, Y. et al. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. Cancer Biomark. 24, 371–382 (2019).
pubmed: 30883337
Wang, C. Q. et al. Relation between the expression of mitotic centromere-associated kinesin and the progression of squamous cell carcinoma of the tongue. Oral Surg. Oral. Med. Oral Pathol. Oral Radiol. 117, 353–360 (2014).
pubmed: 24445227
Li, X. et al. Kinesin family members KIF2C/4A/10/11/14/18B/20A/23 predict poor prognosis and promote cell proliferation in hepatocellular carcinoma. Am. J. Transl. Res. 12, 1614–1639 (2020).
pubmed: 32509165
pmcid: 7270015
Nakamura, Y. et al. Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br. J. Cancer 97, 543–549 (2007).
pubmed: 17653072
pmcid: 2360338
Gnjatic, S. et al. NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int. J. Cancer 127, 381–393 (2010).
pubmed: 19937794
Hirokawa, N., Noda, Y. & Okada, Y. Kinesin and dynein superfamily proteins in organelle transport and cell division. Curr. Opin. Cell Biol. 10, 60–73 (1998).
pubmed: 9484596
Sharp, D. J., Rogers, G. C. & Scholey, J. M. Microtubule motors in mitosis. Nature 407, 41–47 (2000).
pubmed: 10993066
Dominguez-Brauer, C. et al. Targeting mitosis in cancer: Emerging strategies. Mol. Cell 60, 524–536 (2015).
pubmed: 26590712
Hedrick, D. G., Stout, J. R. & Walczak, C. E. Effects of anti-microtubule agents on microtubule organization in cells lacking the kinesin-13 MCAK. Cell Cycle 7, 2146–2156 (2008).
pubmed: 18635958
Zhao, F. et al. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLoS ONE 9, e113478 (2014).
pubmed: 25411964
pmcid: 4239070
Ganguly, A., Yang, H. & Cabral, F. Overexpression of mitotic centromere-associated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Mol. Cancer Ther. 10, 929–937 (2011).
pubmed: 21471284
pmcid: 3112244
Liu, X., Chen, Y., Li, Y., Petersen, R. B. & Huang, K. Targeting mitosis exit: A brake for cancer cell proliferation. Biochim. Biophys. Acta Rev. Cancer 2019, 179–191 (1871).
Lucanus, A. J. & Yip, G. W. Kinesin superfamily: Roles in breast cancer, patient prognosis and therapeutics. Oncogene 37, 833–838 (2018).
pubmed: 29059174
Wei, S. et al. KIF2C: a novel link between Wnt/beta-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma. Protein Cell 12, 788–809 (2021).
pubmed: 32748349
Tu, B. et al. In silico analysis of the correlation of KIF2C with prognosis and immune infiltration in glioma. Comput. Math. Methods Med 2022, 6320828 (2022).
pubmed: 35387222
pmcid: 8977321
Li, J. et al. Functional and clinical characterization of tumor-infiltrating T cell subpopulations in hepatocellular carcinoma. Front. Genet. 11, 586415 (2020).
pubmed: 33133170
pmcid: 7561438
Mardanpour, K., Rahbar, M., Mardanpour, S., Mardanpour, N. & Rezaei, M. CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilms’ tumor. Tumour Biol. 42, 1010428320975976 (2020).
pubmed: 33283684
Tian, X. M. et al. Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour. Front. Immunol. 13, 920666 (2022).
pubmed: 36172369
pmcid: 9510599